Qualitative interviews and quantitative surveys on mental health, decision making certainty, self esteem and resilience were performed at multiple timepoints on the FRESH cohort participants.
The investigators stress the importance of conducting mental health assessments throughout these trials

Modified IPDA (because of the lentiviral vector) demonstrated sustained reduction in intact provirus even if plasma viral load increased and necessitated restart ART

Rebound virus from participants of the PULSE study #ATI was sequences and IMAP peptides are found in 90-100%

Their peptide pool able to trigger immune responses in transient virus controllers, response varies between donors

All and primary endpoints of viral rebound at 20-24 weeks. When long acting bNAbs will still be circulating.

The studies that have presented #ATI data have shown distinct patterns of rebound
- quick
- delayed
- vascilating with some control

A really nice summary of where CAR-T cell therapy in #HIVcure is at.

Briefly - promising but a while to go to address issues including lack of HIV antigens in PLWH on ART

I’ll be coming back to relisten to this talk!

Several strategies explored to improve CAR-T cell activity in HIV

Challenges in CAR-T cell therapy for #HIvcure and opportunities to address these issues

N=32 majority female
16 reviewed by safety monitoring committee and 2/3 had experienced viral rebound by week 12.
Possibly indicating subtype C virus not sensitive to the bNAbs?

Study stopped enrolment as per pre-specified criteria. Further virology immunology and reservoir data to follow

Whoops what did I do to my photo???

Here is the poster

Implications for #HIVcure?

TB/HIV is an incredibly common coinfection and we need to understand sites and mechanisms of persistence if we are to address barriers to a cure